MLTX icon

MoonLake Immunotherapeutics

52.67 USD
+0.53
1.02%
At close Dec 24, 4:00 PM EST
1 day
1.02%
5 days
-6.48%
1 month
-2.77%
3 months
-2.93%
6 months
36.06%
Year to date
-11.55%
1 year
-14.41%
5 years
329.96%
10 years
329.96%
 

About: MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Employees: 50

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

122% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 23

21% more call options, than puts

Call options by funds: $6.05M | Put options by funds: $5M

16% more capital invested

Capital invested by funds: $2.71B [Q2] → $3.14B (+$429M) [Q3]

0.98% more ownership

Funds ownership: 98.04% [Q2] → 99.02% (+0.98%) [Q3]

2% less funds holding

Funds holding: 111 [Q2] → 109 (-2) [Q3]

10% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 20

20% less funds holding in top 10

Funds holding in top 10: 5 [Q2] → 4 (-1) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$73
39%
upside
Avg. target
$87
64%
upside
High target
$100
90%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
38% 1-year accuracy
118 / 313 met price target
90%upside
$100
Buy
Reiterated
14 Nov 2024
Wedbush
Yun Zhong
25% 1-year accuracy
1 / 4 met price target
39%upside
$73
Outperform
Assumed
5 Nov 2024

Financial journalist opinion

Neutral
GlobeNewsWire
3 months ago
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Update for investors and analysts live from New York on Wednesday, September 11 from 2024, from 9:00 – 10:30 EST/06:00 – 08:30 PST/14:00 – 16:30 CET The event will provide business updates from MoonLake's CEO Jorge Santos da Silva, CSO Kristian Reich and CFO Matthias Bodenstedt and include details on the Phase 3 programs for our investigational Nanobody® sonelokimab (SLK) in hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). In addition, MoonLake will provide pipeline updates and details on additional catalysts for the 2024-2026 period, including for trials in new indications such as the Phase 2 trials of SLK in palmo-plantar pustulosis (PPP).
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
Positive
Seeking Alpha
5 months ago
MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward
MoonLake Immunotherapeutics launched VELA-1 and VELA-2 as two studies using sonelokimab for the treatment of patients with Hidradenitis Suppurativa; Topline 16-week primary endpoint expected end of 2026. The global hidradenitis suppurativa market is expected to reach $1 billion by 2029. The initiation of the IZAR program, using sonelokimab for patients with Psoriatic Arthritis, is expected to launch in Q4 of 2024; Primary endpoint data is expected at the end of 2026.
MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward
Neutral
GlobeNewsWire
7 months ago
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody ® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
Positive
Seeking Alpha
7 months ago
MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion
MoonLake develops sonelokimab, targeting large markets like psoriasis and hidradenitis suppurativa, with promising Phase 2 data. Despite a competitive landscape with established IL-17 inhibitors, MoonLake's nanobody potentially offers better tissue penetration. Financially, MoonLake is secure with a cash runway for nearly seven years, preparing for Phase 3 trials without immediate funding needs.
MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion
Neutral
GlobeNewsWire
7 months ago
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program of the Nanobody ® sonelokimab in hidradenitis suppurativa (HS) and outlined the development plan with topline results anticipated in mid-2025 Reported significant improvements observed across all key outcomes with sonelokimab over 24 weeks in the ARGO Phase 2 trial in active psoriatic arthritis (PsA) including unprecedented multi-domain responses across joints, skin and other domains, supporting potential best-in-class profile of sonelokimab Announced the imminent commencement of four additional clinical trials of sonelokimab across dermatology, and rheumatology, including innovative trials in palmo-plantar pustulosis (PPP), juvenile HS and seronegative spondyloarthritis Ended the first quarter with $547.1 million in cash, cash equivalents and short-term marketable debt securities, expected to support a roadmap rich in potential catalysts and a cash runway to the end of 2026 ZUG, Switzerland, May 7, 2024 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the first quarter of 2024. Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2024 is shaping up to be a strong year for MoonLake.
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
Neutral
GlobeNewsWire
8 months ago
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
Neutral
Business Wire
8 months ago
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
SAN FRANCISCO & ZUG, Switzerland--(BUSINESS WIRE)--MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases. The two companies will collaborate to maximize the impact of MoonLake's nanobody-based therapy in hidradenitis suppurativa (HS) and acti.
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
Positive
Investors Business Daily
9 months ago
MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
Biotech stock MoonLake popped Monday after the company said its experimental psoriatic arthritis treatment beat out AbbVie's Humira.
MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
Neutral
GlobeNewsWire
9 months ago
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
MoonLake announces significant improvements with Nanobody ® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
Neutral
GlobeNewsWire
9 months ago
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody ® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
Charts implemented using Lightweight Charts™